Cargando…

Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis

PURPOSE: To evaluate the effect of the 21-gene recurrence score (RS) assay in breast cancer-specific mortality (BCSM) and decision-making for chemotherapy in older (aged ≥65 years) breast cancer. METHODS: We retrospectively included older patients with T1-2N0 and estrogen receptor-positive breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ping, Zhang, Wen-Wen, Bao, Yong, Wang, Jun, Lian, Chen-Lu, He, Zhen-Yu, Wu, San-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718160/ https://www.ncbi.nlm.nih.gov/pubmed/33278648 http://dx.doi.org/10.1016/j.breast.2020.11.018

Ejemplares similares

Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
por: Wu, San-Gang, et al.
Publicado: (2019)

Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases
por: Chen, Wei-Rong, et al.
Publicado: (2019)

21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery
por: Wu, San-Gang, et al.
Publicado: (2019)

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
por: Wang, Jun, et al.
Publicado: (2018)

Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study
por: Liu, Kai-Hua, et al.
Publicado: (2019)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
por: Zhang, Wen-Wen, et al.
Publicado: (2019)

Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
por: Yu, Jing, et al.
Publicado: (2021)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

Molecular characterization of breast cancer needle core biopsy specimens by the 21‐gene Breast Recurrence Score test
por: Jakubowski, Debbie M., et al.
Publicado: (2020)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Omission of Postoperative Radiotherapy in Women Aged 65 Years or Older With Tubular Carcinoma of the Breast After Breast-Conserving Surgery
por: Wu, San-Gang, et al.
Publicado: (2018)

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013
por: Parsons, Benjamin M., et al.
Publicado: (2016)

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher
por: Ma, Sung Jun, et al.
Publicado: (2020)

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making
por: Lian, Chen-Lu, et al.
Publicado: (2021)

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
por: Walter, Vincent P., et al.
Publicado: (2020)

The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database
por: Choi, In Sil, et al.
Publicado: (2020)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
por: Wu, San-Gang, et al.
Publicado: (2020)

Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up
por: Turashvili, Gulisa, et al.
Publicado: (2018)

Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2021)

Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score
por: Gao, Weiqi, et al.
Publicado: (2020)

Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
por: Chen, Rui, et al.
Publicado: (2021)

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
por: Soliman, Hatem, et al.
Publicado: (2020)

Clinical application of the 21-gene oncotype recurrence score in an older cohort: A single center experience
por: Chiru, E.D., et al.
Publicado: (2023)

Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30
por: Park, Seho, et al.
Publicado: (2019)

Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
por: Alkushi, Abdulmohsen, et al.
Publicado: (2020)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
por: Sparano, Joseph A., et al.
Publicado: (2021)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

Impact of AJCC prognostic staging on prognosis and postmastectomy radiotherapy decision-making in hormone receptor-positive and HER2-positive breast cancer
por: Li, Guan-Qiao, et al.
Publicado: (2022)

The Effect of Post-mastectomy Radiotherapy in Patients With Metaplastic Breast Cancer: An Analysis of SEER Database
por: Wang, Jun, et al.
Publicado: (2019)

Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
por: Makower, Della, et al.
Publicado: (2021)

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
por: Bilani, Nadeem, et al.
Publicado: (2022)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

The addition of radiotherapy to breast-conserving surgery improves survival for elderly patients with early breast cancer
por: Yang, Shi-Ping, et al.
Publicado: (2022)

Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
por: Yang, David D., et al.
Publicado: (2020)

Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer
por: Zhu, Lizhe, et al.
Publicado: (2019)

Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer
por: Zhu, Lizhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5n2kt8m0rd40adi4htls8g4gj7